News
Merck KGaA out-licenses osteoarthritis programme to Novartis
Germany’s Merck KGaA has entered into an out-licensing agreement with Novartis for the development of an osteoarthritis clinical-stage programme.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Germany’s Merck KGaA has entered into an out-licensing agreement with Novartis for the development of an osteoarthritis clinical-stage programme.